You can help fight the fastest increasing cause of cancer mortality in Australia

The global burden of Hepatocellular carcinoma (HCC), the third most frequent cause of cancer mortality worldwide, is rapidly increasing due to late detection, limited treatment options available and recurrence due to therapy resistance. Majority of early stage HCC patients tend to be asymptomatic.

Additionally, it is a great challenge to distinguish early HCC from cirrhotic and fatty livers through current clinical biochemical indexes or radiographic evidence. Therefore, the discoveries of novel biomarkers that can effectively and reliably screen high-risk populations, detect HCC at an early stage and monitor response to treatment are urgently needed.

You can help progress this important work by making a donation today.

Current projects

View all projects

Epithelial-to-mesenchymal transition of HCC: Liquid biopsy-based biomarker discovery

Epithelial-to-mesenchymal transition (EMT) process has important implications for our understanding of HCC progression as its role in the development and advancement of HCC has gained increasing attention in the recent years. This multi-step reprograming process resulting in a phenotype switch from...

Identifying Druggable Targets in Liver Cancer: Cancer Stem Cells targeting

The treatment options available to patients diagnosed with liver cancer are very limited. Recurrence of liver cancer after treatment remains a major problem that needs to be solved. Resistance to radiotherapy and chemotherapy has been attributed to Cancer Stem Cells (CSC). Cancer stem cells (CSCs) represent...

Our team


View Publications


View Collaboration

Opportunities for students

The Liver Cancer Unit currently has two students completing their PhD as part of GMRF’s scholarship program. If you are interested in findng out more about this program please contact the Foundation on 07 3394 7284.



View Resources


Contact us and we’ll reply as soon as we can.